Metabolic Acidosis

Patients with end-stage kidney disease may be at higher risk for hypoglycemia, with a disproportionate effect on young, Black and female patients, according to published data.

Among patients with chronic kidney disease, the presence of metabolic acidosis is associated with an increased risk of adverse kidney outcomes and health care costs, according to data published in Kidney Medicine.

The presence of metabolic acidosis increased the risk for major adverse cardiovascular events in patients with non-dialysis dependent chronic kidney disease, study findings showed.

Metabolic acidosis, measured by low serum bicarbonate, was linked to a higher risk of chronic kidney disease progression in children with glomerular disease, according to findings from a published study.

For patients with chronic kidney disease and diabetes, veverimer appeared to be an effective treatment for metabolic acidosis, as it improved both quality of life and physical function, according to phase 3 trial results. The results were presented virtually at the National Kidney Foundation Spring Clinical Meetings.

Published findings suggest that, for patients with chronic kidney disease, a higher dose of sodium bicarbonate lowered urinary ammonium excretion and increased serum bicarbonate more than a lower dose. However, the higher dose was associated with a greater increase in urinary albumin excretion.

In a published study, researchers suggested a diet high in vegetables and fruit could serve as a modifiable factor to help reduce the risk of chronic kidney disease.